Prime Research

Latest Research

Biosimilar strategy for infliximab by MedDrive™ includes the reference drug

The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab) in April of 1998 for the treatment of Crohn’s disease. It was…

Read More

February 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen…

Read More

Drug Pipeline Quarterly Update: December 2021

These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …